nodes	percent_of_prediction	percent_of_DWPC	metapath
L-Carnitine—SLC22A16—Doxorubicin—thyroid cancer	0.587	0.853	CbGbCtD
L-Carnitine—XDH—Doxorubicin—thyroid cancer	0.101	0.147	CbGbCtD
L-Carnitine—CES1—larynx—thyroid cancer	0.011	0.0972	CbGeAlD
L-Carnitine—SLC22A4—larynx—thyroid cancer	0.00838	0.0741	CbGeAlD
L-Carnitine—SLC25A29—neck—thyroid cancer	0.00824	0.0729	CbGeAlD
L-Carnitine—SLC25A20—Import of palmitoyl-CoA into the mitochondrial matrix—RXRA—thyroid cancer	0.00774	0.0803	CbGpPWpGaD
L-Carnitine—SLC25A20—saliva-secreting gland—thyroid cancer	0.00513	0.0453	CbGeAlD
L-Carnitine—CPT2—Import of palmitoyl-CoA into the mitochondrial matrix—RXRA—thyroid cancer	0.00499	0.0517	CbGpPWpGaD
L-Carnitine—CRAT—saliva-secreting gland—thyroid cancer	0.00497	0.044	CbGeAlD
L-Carnitine—SLC25A20—trachea—thyroid cancer	0.00395	0.035	CbGeAlD
L-Carnitine—SLC25A29—thyroid gland—thyroid cancer	0.00392	0.0347	CbGeAlD
L-Carnitine—CRAT—trachea—thyroid cancer	0.00384	0.0339	CbGeAlD
L-Carnitine—CPT2—saliva-secreting gland—thyroid cancer	0.00383	0.0338	CbGeAlD
L-Carnitine—CROT—thyroid gland—thyroid cancer	0.0036	0.0318	CbGeAlD
L-Carnitine—Hypercalcaemia—Vandetanib—thyroid cancer	0.00349	0.0338	CcSEcCtD
L-Carnitine—SLC25A29—head—thyroid cancer	0.00348	0.0308	CbGeAlD
L-Carnitine—CPT1A—Import of palmitoyl-CoA into the mitochondrial matrix—RXRA—thyroid cancer	0.00346	0.0359	CbGpPWpGaD
L-Carnitine—CPT1A—FOXA2 and FOXA3 transcription factor networks—NKX2-1—thyroid cancer	0.00322	0.0334	CbGpPWpGaD
L-Carnitine—CROT—head—thyroid cancer	0.00319	0.0282	CbGeAlD
L-Carnitine—SLC25A20—thyroid gland—thyroid cancer	0.00313	0.0277	CbGeAlD
L-Carnitine—CPT2—PPAR Alpha Pathway—CDK1—thyroid cancer	0.00309	0.032	CbGpPWpGaD
L-Carnitine—CRAT—thyroid gland—thyroid cancer	0.00303	0.0268	CbGeAlD
L-Carnitine—CES1—neck—thyroid cancer	0.00291	0.0258	CbGeAlD
L-Carnitine—CPT2—PPAR Alpha Pathway—RXRA—thyroid cancer	0.00287	0.0297	CbGpPWpGaD
L-Carnitine—Gastrointestinal symptom NOS—Sorafenib—thyroid cancer	0.00278	0.027	CcSEcCtD
L-Carnitine—SLC25A20—head—thyroid cancer	0.00278	0.0245	CbGeAlD
L-Carnitine—CRAT—head—thyroid cancer	0.00269	0.0238	CbGeAlD
L-Carnitine—CPT1A—thyroid gland—thyroid cancer	0.00246	0.0218	CbGeAlD
L-Carnitine—SLC25A29—lymph node—thyroid cancer	0.00244	0.0215	CbGeAlD
L-Carnitine—CPT2—thyroid gland—thyroid cancer	0.00233	0.0207	CbGeAlD
L-Carnitine—CROT—lymph node—thyroid cancer	0.00223	0.0198	CbGeAlD
L-Carnitine—SLC22A4—neck—thyroid cancer	0.00222	0.0196	CbGeAlD
L-Carnitine—CPT1A—head—thyroid cancer	0.00218	0.0193	CbGeAlD
L-Carnitine—CPT1A—PPAR Alpha Pathway—CDK1—thyroid cancer	0.00214	0.0222	CbGpPWpGaD
L-Carnitine—CPT2—head—thyroid cancer	0.00207	0.0183	CbGeAlD
L-Carnitine—CPT1A—RORA activates circadian gene expression—RXRA—thyroid cancer	0.00205	0.0212	CbGpPWpGaD
L-Carnitine—SLC22A16—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—thyroid cancer	0.00201	0.0208	CbGpPWpGaD
L-Carnitine—CPT1A—PPAR Alpha Pathway—RXRA—thyroid cancer	0.00199	0.0206	CbGpPWpGaD
L-Carnitine—SLC25A20—lymph node—thyroid cancer	0.00194	0.0172	CbGeAlD
L-Carnitine—CRAT—lymph node—thyroid cancer	0.00189	0.0167	CbGeAlD
L-Carnitine—Atrial fibrillation—Vandetanib—thyroid cancer	0.00186	0.018	CcSEcCtD
L-Carnitine—Gastritis—Vandetanib—thyroid cancer	0.00156	0.0151	CcSEcCtD
L-Carnitine—CPT1A—lymph node—thyroid cancer	0.00153	0.0135	CbGeAlD
L-Carnitine—Influenza—Vandetanib—thyroid cancer	0.00152	0.0148	CcSEcCtD
L-Carnitine—CES1—Fluoropyrimidine Activity—SMUG1—thyroid cancer	0.00149	0.0154	CbGpPWpGaD
L-Carnitine—Bronchitis—Vandetanib—thyroid cancer	0.00146	0.0142	CcSEcCtD
L-Carnitine—CPT2—lymph node—thyroid cancer	0.00145	0.0128	CbGeAlD
L-Carnitine—CES1—thyroid gland—thyroid cancer	0.00139	0.0123	CbGeAlD
L-Carnitine—Weight decreased—Vandetanib—thyroid cancer	0.00137	0.0133	CcSEcCtD
L-Carnitine—Depression—Vandetanib—thyroid cancer	0.00135	0.0131	CcSEcCtD
L-Carnitine—SLC22A4—trachea—thyroid cancer	0.00134	0.0118	CbGeAlD
L-Carnitine—Renal failure—Vandetanib—thyroid cancer	0.00133	0.0129	CcSEcCtD
L-Carnitine—Urinary tract infection—Vandetanib—thyroid cancer	0.00132	0.0128	CcSEcCtD
L-Carnitine—CPT2—PPAR Alpha Pathway—CCND1—thyroid cancer	0.00129	0.0133	CbGpPWpGaD
L-Carnitine—Sinusitis—Vandetanib—thyroid cancer	0.00127	0.0123	CcSEcCtD
L-Carnitine—CES1—head—thyroid cancer	0.00123	0.0109	CbGeAlD
L-Carnitine—CROT—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.00123	0.0127	CbGpPWpGaD
L-Carnitine—Haemoglobin—Vandetanib—thyroid cancer	0.00122	0.0119	CcSEcCtD
L-Carnitine—Haemorrhage—Vandetanib—thyroid cancer	0.00122	0.0118	CcSEcCtD
L-Carnitine—CPT1A—SIDS Susceptibility Pathways—RET—thyroid cancer	0.0012	0.0124	CbGpPWpGaD
L-Carnitine—SLC22A5—saliva-secreting gland—thyroid cancer	0.00115	0.0101	CbGeAlD
L-Carnitine—Eye disorder—Vandetanib—thyroid cancer	0.00114	0.011	CcSEcCtD
L-Carnitine—CPT1A—SIDS Susceptibility Pathways—THRB—thyroid cancer	0.00112	0.0116	CbGpPWpGaD
L-Carnitine—Angiopathy—Vandetanib—thyroid cancer	0.0011	0.0107	CcSEcCtD
L-Carnitine—CPT1A—Circadian Clock—RXRA—thyroid cancer	0.00109	0.0113	CbGpPWpGaD
L-Carnitine—Arrhythmia—Vandetanib—thyroid cancer	0.00109	0.0105	CcSEcCtD
L-Carnitine—SLC22A4—thyroid gland—thyroid cancer	0.00106	0.00935	CbGeAlD
L-Carnitine—Gastritis—Sorafenib—thyroid cancer	0.00105	0.0102	CcSEcCtD
L-Carnitine—SLC25A20—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.00104	0.0108	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.00104	0.0108	CbGpPWpGaD
L-Carnitine—Dysgeusia—Vandetanib—thyroid cancer	0.00104	0.0101	CcSEcCtD
L-Carnitine—MPO—head—thyroid cancer	0.00103	0.00909	CbGeAlD
L-Carnitine—SLCO1B1—Recycling of bile acids and salts—RXRA—thyroid cancer	0.00102	0.0106	CbGpPWpGaD
L-Carnitine—Muscle spasms—Vandetanib—thyroid cancer	0.00102	0.00988	CcSEcCtD
L-Carnitine—Myasthenia—Epirubicin—thyroid cancer	0.000961	0.00933	CcSEcCtD
L-Carnitine—CPT1A—Circadian rythm related genes—NKX2-1—thyroid cancer	0.000955	0.00989	CbGpPWpGaD
L-Carnitine—SLC25A20—Fatty acid, triacylglycerol, and ketone body metabolism—RXRA—thyroid cancer	0.000946	0.00981	CbGpPWpGaD
L-Carnitine—Weight decreased—Sorafenib—thyroid cancer	0.000927	0.009	CcSEcCtD
L-Carnitine—Cough—Vandetanib—thyroid cancer	0.000924	0.00897	CcSEcCtD
L-Carnitine—Convulsion—Vandetanib—thyroid cancer	0.000917	0.00891	CcSEcCtD
L-Carnitine—Hypertension—Vandetanib—thyroid cancer	0.000914	0.00887	CcSEcCtD
L-Carnitine—SLC22A16—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000914	0.00947	CbGpPWpGaD
L-Carnitine—SLC22A16—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000914	0.00947	CbGpPWpGaD
L-Carnitine—CPT2—PPARA activates gene expression—RXRA—thyroid cancer	0.000904	0.00937	CbGpPWpGaD
L-Carnitine—Chest pain—Vandetanib—thyroid cancer	0.000901	0.00875	CcSEcCtD
L-Carnitine—Renal failure—Sorafenib—thyroid cancer	0.000898	0.00872	CcSEcCtD
L-Carnitine—Anxiety—Vandetanib—thyroid cancer	0.000898	0.00872	CcSEcCtD
L-Carnitine—CPT1A—PPAR Alpha Pathway—CCND1—thyroid cancer	0.000892	0.00924	CbGpPWpGaD
L-Carnitine—Myasthenia—Doxorubicin—thyroid cancer	0.000889	0.00863	CcSEcCtD
L-Carnitine—CPT2—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—RXRA—thyroid cancer	0.000885	0.00917	CbGpPWpGaD
L-Carnitine—SLC22A5—trachea—thyroid cancer	0.000884	0.00782	CbGeAlD
L-Carnitine—Hypercalcaemia—Epirubicin—thyroid cancer	0.000869	0.00844	CcSEcCtD
L-Carnitine—CES1—lymph node—thyroid cancer	0.000861	0.00762	CbGeAlD
L-Carnitine—Infection—Vandetanib—thyroid cancer	0.000858	0.00833	CcSEcCtD
L-Carnitine—CROT—Metabolism—MINPP1—thyroid cancer	0.000848	0.00879	CbGpPWpGaD
L-Carnitine—Haemoglobin—Sorafenib—thyroid cancer	0.000825	0.00801	CcSEcCtD
L-Carnitine—SLC22A8—head—thyroid cancer	0.000821	0.00726	CbGeAlD
L-Carnitine—Haemorrhage—Sorafenib—thyroid cancer	0.00082	0.00797	CcSEcCtD
L-Carnitine—CPT1A—Circadian Clock—HIF1A—thyroid cancer	0.00081	0.0084	CbGpPWpGaD
L-Carnitine—Hypercalcaemia—Doxorubicin—thyroid cancer	0.000804	0.00781	CcSEcCtD
L-Carnitine—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.000787	0.00764	CcSEcCtD
L-Carnitine—Amblyopia—Epirubicin—thyroid cancer	0.000782	0.00759	CcSEcCtD
L-Carnitine—Insomnia—Vandetanib—thyroid cancer	0.000781	0.00759	CcSEcCtD
L-Carnitine—Paraesthesia—Vandetanib—thyroid cancer	0.000776	0.00753	CcSEcCtD
L-Carnitine—Dyspnoea—Vandetanib—thyroid cancer	0.00077	0.00748	CcSEcCtD
L-Carnitine—CES1—E2F transcription factor network—CDK1—thyroid cancer	0.000764	0.00792	CbGpPWpGaD
L-Carnitine—Dyspepsia—Vandetanib—thyroid cancer	0.000761	0.00738	CcSEcCtD
L-Carnitine—Decreased appetite—Vandetanib—thyroid cancer	0.000751	0.00729	CcSEcCtD
L-Carnitine—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.000746	0.00724	CcSEcCtD
L-Carnitine—Angiopathy—Sorafenib—thyroid cancer	0.000744	0.00723	CcSEcCtD
L-Carnitine—SLC22A4—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—thyroid cancer	0.000744	0.00771	CbGpPWpGaD
L-Carnitine—CPT1A—SIDS Susceptibility Pathways—PRKAR1A—thyroid cancer	0.000741	0.00768	CbGpPWpGaD
L-Carnitine—Pain—Vandetanib—thyroid cancer	0.000739	0.00717	CcSEcCtD
L-Carnitine—Constipation—Vandetanib—thyroid cancer	0.000739	0.00717	CcSEcCtD
L-Carnitine—Arrhythmia—Sorafenib—thyroid cancer	0.000733	0.00712	CcSEcCtD
L-Carnitine—Amblyopia—Doxorubicin—thyroid cancer	0.000723	0.00702	CcSEcCtD
L-Carnitine—CRAT—Metabolism—MINPP1—thyroid cancer	0.000721	0.00747	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism—MINPP1—thyroid cancer	0.000721	0.00747	CbGpPWpGaD
L-Carnitine—CROT—Metabolism—NDUFA13—thyroid cancer	0.000721	0.00747	CbGpPWpGaD
L-Carnitine—MPO—lymph node—thyroid cancer	0.000719	0.00636	CbGeAlD
L-Carnitine—Gastrointestinal pain—Vandetanib—thyroid cancer	0.000707	0.00686	CcSEcCtD
L-Carnitine—SLC22A5—thyroid gland—thyroid cancer	0.0007	0.00619	CbGeAlD
L-Carnitine—Dysgeusia—Sorafenib—thyroid cancer	0.000699	0.00679	CcSEcCtD
L-Carnitine—Cardiovascular disorder—Epirubicin—thyroid cancer	0.000687	0.00667	CcSEcCtD
L-Carnitine—Muscle spasms—Sorafenib—thyroid cancer	0.000687	0.00667	CcSEcCtD
L-Carnitine—SLC22A16—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000684	0.00709	CbGpPWpGaD
L-Carnitine—Abdominal pain—Vandetanib—thyroid cancer	0.000683	0.00663	CcSEcCtD
L-Carnitine—Body temperature increased—Vandetanib—thyroid cancer	0.000683	0.00663	CcSEcCtD
L-Carnitine—CROT—Metabolism—CHST14—thyroid cancer	0.000678	0.00702	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000672	0.00697	CbGpPWpGaD
L-Carnitine—Anaemia—Sorafenib—thyroid cancer	0.00066	0.00641	CcSEcCtD
L-Carnitine—SLC22A4—lymph node—thyroid cancer	0.000657	0.00581	CbGeAlD
L-Carnitine—Cardiovascular disorder—Doxorubicin—thyroid cancer	0.000636	0.00617	CcSEcCtD
L-Carnitine—CPT1A—PPARA activates gene expression—RXRA—thyroid cancer	0.000627	0.00649	CbGpPWpGaD
L-Carnitine—Cough—Sorafenib—thyroid cancer	0.000623	0.00605	CcSEcCtD
L-Carnitine—Asthenia—Vandetanib—thyroid cancer	0.00062	0.00602	CcSEcCtD
L-Carnitine—Hypertension—Sorafenib—thyroid cancer	0.000617	0.00599	CcSEcCtD
L-Carnitine—CPT1A—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—RXRA—thyroid cancer	0.000613	0.00636	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism—NDUFA13—thyroid cancer	0.000613	0.00635	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism—NDUFA13—thyroid cancer	0.000613	0.00635	CbGpPWpGaD
L-Carnitine—Pruritus—Vandetanib—thyroid cancer	0.000611	0.00594	CcSEcCtD
L-Carnitine—CPT2—Fatty acid, triacylglycerol, and ketone body metabolism—RXRA—thyroid cancer	0.00061	0.00632	CbGpPWpGaD
L-Carnitine—Myalgia—Sorafenib—thyroid cancer	0.000608	0.0059	CcSEcCtD
L-Carnitine—Injection site reaction—Epirubicin—thyroid cancer	0.0006	0.00583	CcSEcCtD
L-Carnitine—SLC25A20—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—thyroid cancer	0.000597	0.00619	CbGpPWpGaD
L-Carnitine—Hyperkalaemia—Epirubicin—thyroid cancer	0.000593	0.00576	CcSEcCtD
L-Carnitine—Diarrhoea—Vandetanib—thyroid cancer	0.000591	0.00574	CcSEcCtD
L-Carnitine—Melaena—Epirubicin—thyroid cancer	0.00059	0.00573	CcSEcCtD
L-Carnitine—CPT1A—SIDS Susceptibility Pathways—SST—thyroid cancer	0.000586	0.00607	CbGpPWpGaD
L-Carnitine—Infection—Sorafenib—thyroid cancer	0.000579	0.00562	CcSEcCtD
L-Carnitine—SLC25A20—Metabolism—CHST14—thyroid cancer	0.000576	0.00597	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism—CHST14—thyroid cancer	0.000576	0.00597	CbGpPWpGaD
L-Carnitine—Dizziness—Vandetanib—thyroid cancer	0.000571	0.00555	CcSEcCtD
L-Carnitine—CPT2—PPARA activates gene expression—PPARG—thyroid cancer	0.000571	0.00592	CbGpPWpGaD
L-Carnitine—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—thyroid cancer	0.000559	0.0058	CbGpPWpGaD
L-Carnitine—CPT2—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—thyroid cancer	0.000559	0.00579	CbGpPWpGaD
L-Carnitine—Anorexia—Sorafenib—thyroid cancer	0.000556	0.00539	CcSEcCtD
L-Carnitine—Injection site reaction—Doxorubicin—thyroid cancer	0.000555	0.00539	CcSEcCtD
L-Carnitine—Cramps of lower extremities—Epirubicin—thyroid cancer	0.000555	0.00539	CcSEcCtD
L-Carnitine—Vomiting—Vandetanib—thyroid cancer	0.000549	0.00533	CcSEcCtD
L-Carnitine—Hyperkalaemia—Doxorubicin—thyroid cancer	0.000549	0.00533	CcSEcCtD
L-Carnitine—CROT—Metabolism—HPGD—thyroid cancer	0.000546	0.00566	CbGpPWpGaD
L-Carnitine—Melaena—Doxorubicin—thyroid cancer	0.000546	0.0053	CcSEcCtD
L-Carnitine—Rash—Vandetanib—thyroid cancer	0.000545	0.00529	CcSEcCtD
L-Carnitine—Dermatitis—Vandetanib—thyroid cancer	0.000544	0.00528	CcSEcCtD
L-Carnitine—Headache—Vandetanib—thyroid cancer	0.000541	0.00526	CcSEcCtD
L-Carnitine—SLCO1B1—Bile acid and bile salt metabolism—RXRA—thyroid cancer	0.000534	0.00553	CbGpPWpGaD
L-Carnitine—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.000531	0.00516	CcSEcCtD
L-Carnitine—Hypertonia—Epirubicin—thyroid cancer	0.000529	0.00514	CcSEcCtD
L-Carnitine—Dyspnoea—Sorafenib—thyroid cancer	0.00052	0.00505	CcSEcCtD
L-Carnitine—Nausea—Vandetanib—thyroid cancer	0.000513	0.00498	CcSEcCtD
L-Carnitine—Cramps of lower extremities—Doxorubicin—thyroid cancer	0.000513	0.00498	CcSEcCtD
L-Carnitine—Dyspepsia—Sorafenib—thyroid cancer	0.000513	0.00498	CcSEcCtD
L-Carnitine—Decreased appetite—Sorafenib—thyroid cancer	0.000507	0.00492	CcSEcCtD
L-Carnitine—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—thyroid cancer	0.000506	0.00524	CbGpPWpGaD
L-Carnitine—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000503	0.00489	CcSEcCtD
L-Carnitine—Constipation—Sorafenib—thyroid cancer	0.000498	0.00484	CcSEcCtD
L-Carnitine—Pain—Sorafenib—thyroid cancer	0.000498	0.00484	CcSEcCtD
L-Carnitine—Hypertonia—Doxorubicin—thyroid cancer	0.00049	0.00475	CcSEcCtD
L-Carnitine—CES1—NRF2 pathway—SLC5A5—thyroid cancer	0.000485	0.00502	CbGpPWpGaD
L-Carnitine—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000477	0.00463	CcSEcCtD
L-Carnitine—CPT1A—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000466	0.00483	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism—HPGD—thyroid cancer	0.000464	0.00481	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism—HPGD—thyroid cancer	0.000464	0.00481	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism—MINPP1—thyroid cancer	0.000464	0.00481	CbGpPWpGaD
L-Carnitine—SLC22A16—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000464	0.00481	CbGpPWpGaD
L-Carnitine—SLC22A16—Transmembrane transport of small molecules—CP—thyroid cancer	0.000464	0.00481	CbGpPWpGaD
L-Carnitine—Abdominal pain—Sorafenib—thyroid cancer	0.000461	0.00447	CcSEcCtD
L-Carnitine—Body temperature increased—Sorafenib—thyroid cancer	0.000461	0.00447	CcSEcCtD
L-Carnitine—SLC22A16—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000457	0.00473	CbGpPWpGaD
L-Carnitine—CROT—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000443	0.00459	CbGpPWpGaD
L-Carnitine—SLC22A5—lymph node—thyroid cancer	0.000435	0.00384	CbGeAlD
L-Carnitine—Hypersensitivity—Sorafenib—thyroid cancer	0.000429	0.00417	CcSEcCtD
L-Carnitine—CPT1A—Fatty acid, triacylglycerol, and ketone body metabolism—RXRA—thyroid cancer	0.000423	0.00438	CbGpPWpGaD
L-Carnitine—Asthenia—Sorafenib—thyroid cancer	0.000418	0.00406	CcSEcCtD
L-Carnitine—Pruritus—Sorafenib—thyroid cancer	0.000412	0.004	CcSEcCtD
L-Carnitine—CES1—NRF2 pathway—RXRA—thyroid cancer	0.000407	0.00422	CbGpPWpGaD
L-Carnitine—Diarrhoea—Sorafenib—thyroid cancer	0.000399	0.00387	CcSEcCtD
L-Carnitine—CES1—Fluoropyrimidine Activity—TP53—thyroid cancer	0.000396	0.0041	CbGpPWpGaD
L-Carnitine—CPT1A—PPARA activates gene expression—PPARG—thyroid cancer	0.000396	0.0041	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism—NDUFA13—thyroid cancer	0.000395	0.00409	CbGpPWpGaD
L-Carnitine—Gastritis—Epirubicin—thyroid cancer	0.000388	0.00377	CcSEcCtD
L-Carnitine—CPT1A—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—thyroid cancer	0.000387	0.00401	CbGpPWpGaD
L-Carnitine—Muscular weakness—Epirubicin—thyroid cancer	0.000387	0.00375	CcSEcCtD
L-Carnitine—Dizziness—Sorafenib—thyroid cancer	0.000385	0.00374	CcSEcCtD
L-Carnitine—CPT2—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—thyroid cancer	0.000385	0.00399	CbGpPWpGaD
L-Carnitine—Influenza—Epirubicin—thyroid cancer	0.000379	0.00368	CcSEcCtD
L-Carnitine—CRAT—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000377	0.0039	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000377	0.0039	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism—CHST14—thyroid cancer	0.000371	0.00385	CbGpPWpGaD
L-Carnitine—Vomiting—Sorafenib—thyroid cancer	0.000371	0.0036	CcSEcCtD
L-Carnitine—Rash—Sorafenib—thyroid cancer	0.000368	0.00357	CcSEcCtD
L-Carnitine—Dermatitis—Sorafenib—thyroid cancer	0.000367	0.00356	CcSEcCtD
L-Carnitine—Headache—Sorafenib—thyroid cancer	0.000365	0.00355	CcSEcCtD
L-Carnitine—Bronchitis—Epirubicin—thyroid cancer	0.000364	0.00354	CcSEcCtD
L-Carnitine—Gastritis—Doxorubicin—thyroid cancer	0.000359	0.00348	CcSEcCtD
L-Carnitine—Muscular weakness—Doxorubicin—thyroid cancer	0.000358	0.00347	CcSEcCtD
L-Carnitine—CES1—NRF2 pathway—NRG1—thyroid cancer	0.000352	0.00365	CbGpPWpGaD
L-Carnitine—CPT1A—SIDS Susceptibility Pathways—HIF1A—thyroid cancer	0.000352	0.00365	CbGpPWpGaD
L-Carnitine—Influenza—Doxorubicin—thyroid cancer	0.00035	0.0034	CcSEcCtD
L-Carnitine—SLC22A16—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000348	0.0036	CbGpPWpGaD
L-Carnitine—Nausea—Sorafenib—thyroid cancer	0.000346	0.00336	CcSEcCtD
L-Carnitine—Weight increased—Epirubicin—thyroid cancer	0.000345	0.00335	CcSEcCtD
L-Carnitine—Weight decreased—Epirubicin—thyroid cancer	0.000343	0.00333	CcSEcCtD
L-Carnitine—SLC22A4—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000338	0.00351	CbGpPWpGaD
L-Carnitine—SLC22A4—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000338	0.00351	CbGpPWpGaD
L-Carnitine—Bronchitis—Doxorubicin—thyroid cancer	0.000337	0.00327	CcSEcCtD
L-Carnitine—Renal failure—Epirubicin—thyroid cancer	0.000332	0.00322	CcSEcCtD
L-Carnitine—Urinary tract infection—Epirubicin—thyroid cancer	0.000328	0.00319	CcSEcCtD
L-Carnitine—CPT1A—FOXA2 and FOXA3 transcription factor networks—AKT1—thyroid cancer	0.000326	0.00337	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism—MINPP1—thyroid cancer	0.000322	0.00334	CbGpPWpGaD
L-Carnitine—Weight increased—Doxorubicin—thyroid cancer	0.000319	0.0031	CcSEcCtD
L-Carnitine—Weight decreased—Doxorubicin—thyroid cancer	0.000317	0.00308	CcSEcCtD
L-Carnitine—Sinusitis—Epirubicin—thyroid cancer	0.000317	0.00308	CcSEcCtD
L-Carnitine—CROT—Metabolism—TPR—thyroid cancer	0.000314	0.00325	CbGpPWpGaD
L-Carnitine—CROT—Metabolism—PRKAR1A—thyroid cancer	0.000309	0.0032	CbGpPWpGaD
L-Carnitine—Renal failure—Doxorubicin—thyroid cancer	0.000307	0.00298	CcSEcCtD
L-Carnitine—Haemoglobin—Epirubicin—thyroid cancer	0.000305	0.00296	CcSEcCtD
L-Carnitine—Rhinitis—Epirubicin—thyroid cancer	0.000304	0.00295	CcSEcCtD
L-Carnitine—Urinary tract infection—Doxorubicin—thyroid cancer	0.000304	0.00295	CcSEcCtD
L-Carnitine—Haemorrhage—Epirubicin—thyroid cancer	0.000303	0.00294	CcSEcCtD
L-Carnitine—Pharyngitis—Epirubicin—thyroid cancer	0.000301	0.00292	CcSEcCtD
L-Carnitine—CPT2—Metabolism—HPGD—thyroid cancer	0.000299	0.0031	CbGpPWpGaD
L-Carnitine—Oedema peripheral—Epirubicin—thyroid cancer	0.000299	0.0029	CcSEcCtD
L-Carnitine—Sinusitis—Doxorubicin—thyroid cancer	0.000293	0.00285	CcSEcCtD
L-Carnitine—MPO—C-MYB transcription factor network—PTGS2—thyroid cancer	0.000293	0.00303	CbGpPWpGaD
L-Carnitine—SLC22A16—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000292	0.00303	CbGpPWpGaD
L-Carnitine—Eye disorder—Epirubicin—thyroid cancer	0.000283	0.00275	CcSEcCtD
L-Carnitine—MPO—Selenium Micronutrient Network—PTGS2—thyroid cancer	0.000282	0.00292	CbGpPWpGaD
L-Carnitine—Haemoglobin—Doxorubicin—thyroid cancer	0.000282	0.00274	CcSEcCtD
L-Carnitine—Rhinitis—Doxorubicin—thyroid cancer	0.000281	0.00273	CcSEcCtD
L-Carnitine—Haemorrhage—Doxorubicin—thyroid cancer	0.000281	0.00272	CcSEcCtD
L-Carnitine—CROT—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.00028	0.0029	CbGpPWpGaD
L-Carnitine—Pharyngitis—Doxorubicin—thyroid cancer	0.000278	0.0027	CcSEcCtD
L-Carnitine—Oedema peripheral—Doxorubicin—thyroid cancer	0.000276	0.00268	CcSEcCtD
L-Carnitine—Angiopathy—Epirubicin—thyroid cancer	0.000275	0.00267	CcSEcCtD
L-Carnitine—CPT1A—Metabolism—NDUFA13—thyroid cancer	0.000274	0.00284	CbGpPWpGaD
L-Carnitine—Arrhythmia—Epirubicin—thyroid cancer	0.000271	0.00263	CcSEcCtD
L-Carnitine—CPT1A—AMPK Signaling—TP53—thyroid cancer	0.000269	0.00279	CbGpPWpGaD
L-Carnitine—CPT1A—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—thyroid cancer	0.000267	0.00277	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism—TPR—thyroid cancer	0.000267	0.00276	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism—TPR—thyroid cancer	0.000267	0.00276	CbGpPWpGaD
L-Carnitine—MPO—C-MYB transcription factor network—CCND1—thyroid cancer	0.000264	0.00274	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism—PRKAR1A—thyroid cancer	0.000262	0.00272	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism—PRKAR1A—thyroid cancer	0.000262	0.00272	CbGpPWpGaD
L-Carnitine—Eye disorder—Doxorubicin—thyroid cancer	0.000262	0.00255	CcSEcCtD
L-Carnitine—Dysgeusia—Epirubicin—thyroid cancer	0.000258	0.00251	CcSEcCtD
L-Carnitine—CPT1A—Metabolism—CHST14—thyroid cancer	0.000257	0.00267	CbGpPWpGaD
L-Carnitine—Back pain—Epirubicin—thyroid cancer	0.000255	0.00248	CcSEcCtD
L-Carnitine—Angiopathy—Doxorubicin—thyroid cancer	0.000255	0.00247	CcSEcCtD
L-Carnitine—SLC22A5—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000254	0.00263	CbGpPWpGaD
L-Carnitine—SLC22A5—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000254	0.00263	CbGpPWpGaD
L-Carnitine—Muscle spasms—Epirubicin—thyroid cancer	0.000254	0.00246	CcSEcCtD
L-Carnitine—SLC22A4—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000253	0.00262	CbGpPWpGaD
L-Carnitine—Arrhythmia—Doxorubicin—thyroid cancer	0.000251	0.00243	CcSEcCtD
L-Carnitine—XDH—Selenium Micronutrient Network—PTGS2—thyroid cancer	0.000246	0.00255	CbGpPWpGaD
L-Carnitine—CPT1A—Circadian rythm related genes—PPARG—thyroid cancer	0.000244	0.00253	CbGpPWpGaD
L-Carnitine—Anaemia—Epirubicin—thyroid cancer	0.000244	0.00237	CcSEcCtD
L-Carnitine—CPT2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000243	0.00252	CbGpPWpGaD
L-Carnitine—Dysgeusia—Doxorubicin—thyroid cancer	0.000239	0.00232	CcSEcCtD
L-Carnitine—CRAT—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.000238	0.00247	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.000238	0.00247	CbGpPWpGaD
L-Carnitine—Vertigo—Epirubicin—thyroid cancer	0.000237	0.0023	CcSEcCtD
L-Carnitine—Back pain—Doxorubicin—thyroid cancer	0.000236	0.00229	CcSEcCtD
L-Carnitine—CROT—Metabolism—SLC5A5—thyroid cancer	0.000235	0.00243	CbGpPWpGaD
L-Carnitine—Muscle spasms—Doxorubicin—thyroid cancer	0.000235	0.00228	CcSEcCtD
L-Carnitine—Palpitations—Epirubicin—thyroid cancer	0.000233	0.00226	CcSEcCtD
L-Carnitine—Cough—Epirubicin—thyroid cancer	0.00023	0.00224	CcSEcCtD
L-Carnitine—SLC22A8—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.00023	0.00238	CbGpPWpGaD
L-Carnitine—SLC22A8—SLC-mediated transmembrane transport—CP—thyroid cancer	0.00023	0.00238	CbGpPWpGaD
L-Carnitine—Convulsion—Epirubicin—thyroid cancer	0.000229	0.00222	CcSEcCtD
L-Carnitine—Hypertension—Epirubicin—thyroid cancer	0.000228	0.00221	CcSEcCtD
L-Carnitine—MPO—C-MYB transcription factor network—NRAS—thyroid cancer	0.000228	0.00236	CbGpPWpGaD
L-Carnitine—CPT1A—AMPK Signaling—AKT1—thyroid cancer	0.000227	0.00235	CbGpPWpGaD
L-Carnitine—Anaemia—Doxorubicin—thyroid cancer	0.000226	0.00219	CcSEcCtD
L-Carnitine—Chest pain—Epirubicin—thyroid cancer	0.000225	0.00218	CcSEcCtD
L-Carnitine—Myalgia—Epirubicin—thyroid cancer	0.000225	0.00218	CcSEcCtD
L-Carnitine—Anxiety—Epirubicin—thyroid cancer	0.000224	0.00217	CcSEcCtD
L-Carnitine—CROT—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	0.00022	0.00228	CbGpPWpGaD
L-Carnitine—Vertigo—Doxorubicin—thyroid cancer	0.000219	0.00213	CcSEcCtD
L-Carnitine—Palpitations—Doxorubicin—thyroid cancer	0.000216	0.0021	CcSEcCtD
L-Carnitine—Infection—Epirubicin—thyroid cancer	0.000214	0.00208	CcSEcCtD
L-Carnitine—XDH—Metabolism—MINPP1—thyroid cancer	0.000213	0.00221	CbGpPWpGaD
L-Carnitine—Cough—Doxorubicin—thyroid cancer	0.000213	0.00207	CcSEcCtD
L-Carnitine—Convulsion—Doxorubicin—thyroid cancer	0.000212	0.00205	CcSEcCtD
L-Carnitine—MPO—Folate Metabolism—TP53—thyroid cancer	0.000211	0.00219	CbGpPWpGaD
L-Carnitine—Hypertension—Doxorubicin—thyroid cancer	0.000211	0.00205	CcSEcCtD
L-Carnitine—Tachycardia—Epirubicin—thyroid cancer	0.00021	0.00204	CcSEcCtD
L-Carnitine—Chest pain—Doxorubicin—thyroid cancer	0.000208	0.00202	CcSEcCtD
L-Carnitine—Myalgia—Doxorubicin—thyroid cancer	0.000208	0.00202	CcSEcCtD
L-Carnitine—CPT1A—Metabolism—HPGD—thyroid cancer	0.000207	0.00215	CbGpPWpGaD
L-Carnitine—Anxiety—Doxorubicin—thyroid cancer	0.000207	0.00201	CcSEcCtD
L-Carnitine—Anorexia—Epirubicin—thyroid cancer	0.000205	0.00199	CcSEcCtD
L-Carnitine—Hypotension—Epirubicin—thyroid cancer	0.000201	0.00195	CcSEcCtD
L-Carnitine—SLC25A20—Metabolism—SLC5A5—thyroid cancer	0.0002	0.00207	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism—SLC5A5—thyroid cancer	0.0002	0.00207	CbGpPWpGaD
L-Carnitine—Infection—Doxorubicin—thyroid cancer	0.000198	0.00192	CcSEcCtD
L-Carnitine—CROT—Metabolism—RXRA—thyroid cancer	0.000197	0.00205	CbGpPWpGaD
L-Carnitine—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000196	0.00191	CcSEcCtD
L-Carnitine—MPO—C-MYB transcription factor network—KRAS—thyroid cancer	0.000196	0.00203	CbGpPWpGaD
L-Carnitine—Insomnia—Epirubicin—thyroid cancer	0.000195	0.00189	CcSEcCtD
L-Carnitine—Tachycardia—Doxorubicin—thyroid cancer	0.000195	0.00189	CcSEcCtD
L-Carnitine—Paraesthesia—Epirubicin—thyroid cancer	0.000193	0.00188	CcSEcCtD
L-Carnitine—Dyspnoea—Epirubicin—thyroid cancer	0.000192	0.00186	CcSEcCtD
L-Carnitine—CROT—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	0.000192	0.00199	CbGpPWpGaD
L-Carnitine—SLC22A5—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.00019	0.00197	CbGpPWpGaD
L-Carnitine—Anorexia—Doxorubicin—thyroid cancer	0.00019	0.00184	CcSEcCtD
L-Carnitine—Dyspepsia—Epirubicin—thyroid cancer	0.00019	0.00184	CcSEcCtD
L-Carnitine—Decreased appetite—Epirubicin—thyroid cancer	0.000187	0.00182	CcSEcCtD
L-Carnitine—SLC25A20—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	0.000187	0.00194	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	0.000187	0.00194	CbGpPWpGaD
L-Carnitine—Hypotension—Doxorubicin—thyroid cancer	0.000186	0.00181	CcSEcCtD
L-Carnitine—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000186	0.00181	CcSEcCtD
L-Carnitine—Pain—Epirubicin—thyroid cancer	0.000184	0.00179	CcSEcCtD
L-Carnitine—Constipation—Epirubicin—thyroid cancer	0.000184	0.00179	CcSEcCtD
L-Carnitine—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000182	0.00176	CcSEcCtD
L-Carnitine—XDH—Metabolism—NDUFA13—thyroid cancer	0.000181	0.00188	CbGpPWpGaD
L-Carnitine—Insomnia—Doxorubicin—thyroid cancer	0.00018	0.00175	CcSEcCtD
L-Carnitine—Paraesthesia—Doxorubicin—thyroid cancer	0.000179	0.00174	CcSEcCtD
L-Carnitine—Dyspnoea—Doxorubicin—thyroid cancer	0.000178	0.00173	CcSEcCtD
L-Carnitine—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000176	0.00171	CcSEcCtD
L-Carnitine—Dyspepsia—Doxorubicin—thyroid cancer	0.000175	0.0017	CcSEcCtD
L-Carnitine—SLCO1B1—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000175	0.00181	CbGpPWpGaD
L-Carnitine—SLCO1B1—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000175	0.00181	CbGpPWpGaD
L-Carnitine—Decreased appetite—Doxorubicin—thyroid cancer	0.000173	0.00168	CcSEcCtD
L-Carnitine—SLC22A8—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000172	0.00178	CbGpPWpGaD
L-Carnitine—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000172	0.00167	CcSEcCtD
L-Carnitine—CPT2—Metabolism—TPR—thyroid cancer	0.000172	0.00178	CbGpPWpGaD
L-Carnitine—SLC22A4—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000172	0.00178	CbGpPWpGaD
L-Carnitine—SLC22A4—Transmembrane transport of small molecules—CP—thyroid cancer	0.000172	0.00178	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—CHST14—thyroid cancer	0.00017	0.00177	CbGpPWpGaD
L-Carnitine—Constipation—Doxorubicin—thyroid cancer	0.00017	0.00165	CcSEcCtD
L-Carnitine—Pain—Doxorubicin—thyroid cancer	0.00017	0.00165	CcSEcCtD
L-Carnitine—Body temperature increased—Epirubicin—thyroid cancer	0.00017	0.00165	CcSEcCtD
L-Carnitine—Abdominal pain—Epirubicin—thyroid cancer	0.00017	0.00165	CcSEcCtD
L-Carnitine—CPT2—Metabolism—PRKAR1A—thyroid cancer	0.000169	0.00175	CbGpPWpGaD
L-Carnitine—SLC22A4—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000169	0.00175	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000168	0.00174	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism—RXRA—thyroid cancer	0.000168	0.00174	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism—RXRA—thyroid cancer	0.000168	0.00174	CbGpPWpGaD
L-Carnitine—CPT1A—Circadian rythm related genes—PTEN—thyroid cancer	0.000168	0.00174	CbGpPWpGaD
L-Carnitine—MPO—C-MYB transcription factor network—HRAS—thyroid cancer	0.000167	0.00173	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	0.000163	0.00169	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	0.000163	0.00169	CbGpPWpGaD
L-Carnitine—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000163	0.00158	CcSEcCtD
L-Carnitine—SLCO1B1—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000162	0.00168	CbGpPWpGaD
L-Carnitine—Hypersensitivity—Epirubicin—thyroid cancer	0.000159	0.00154	CcSEcCtD
L-Carnitine—Body temperature increased—Doxorubicin—thyroid cancer	0.000158	0.00153	CcSEcCtD
L-Carnitine—Abdominal pain—Doxorubicin—thyroid cancer	0.000158	0.00153	CcSEcCtD
L-Carnitine—Asthenia—Epirubicin—thyroid cancer	0.000155	0.0015	CcSEcCtD
L-Carnitine—CPT2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.000153	0.00159	CbGpPWpGaD
L-Carnitine—Pruritus—Epirubicin—thyroid cancer	0.000152	0.00148	CcSEcCtD
L-Carnitine—Diarrhoea—Epirubicin—thyroid cancer	0.000147	0.00143	CcSEcCtD
L-Carnitine—Hypersensitivity—Doxorubicin—thyroid cancer	0.000147	0.00143	CcSEcCtD
L-Carnitine—Asthenia—Doxorubicin—thyroid cancer	0.000143	0.00139	CcSEcCtD
L-Carnitine—Dizziness—Epirubicin—thyroid cancer	0.000142	0.00138	CcSEcCtD
L-Carnitine—Pruritus—Doxorubicin—thyroid cancer	0.000141	0.00137	CcSEcCtD
L-Carnitine—XDH—Metabolism—HPGD—thyroid cancer	0.000137	0.00142	CbGpPWpGaD
L-Carnitine—Vomiting—Epirubicin—thyroid cancer	0.000137	0.00133	CcSEcCtD
L-Carnitine—Diarrhoea—Doxorubicin—thyroid cancer	0.000136	0.00132	CcSEcCtD
L-Carnitine—Rash—Epirubicin—thyroid cancer	0.000136	0.00132	CcSEcCtD
L-Carnitine—Dermatitis—Epirubicin—thyroid cancer	0.000136	0.00132	CcSEcCtD
L-Carnitine—Headache—Epirubicin—thyroid cancer	0.000135	0.00131	CcSEcCtD
L-Carnitine—Dizziness—Doxorubicin—thyroid cancer	0.000132	0.00128	CcSEcCtD
L-Carnitine—SLCO1B1—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000131	0.00135	CbGpPWpGaD
L-Carnitine—SLC22A5—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000129	0.00134	CbGpPWpGaD
L-Carnitine—SLC22A5—Transmembrane transport of small molecules—CP—thyroid cancer	0.000129	0.00134	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism—SLC5A5—thyroid cancer	0.000129	0.00133	CbGpPWpGaD
L-Carnitine—SLC22A4—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000129	0.00133	CbGpPWpGaD
L-Carnitine—Nausea—Epirubicin—thyroid cancer	0.000128	0.00124	CcSEcCtD
L-Carnitine—SLC22A5—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000127	0.00132	CbGpPWpGaD
L-Carnitine—Vomiting—Doxorubicin—thyroid cancer	0.000127	0.00123	CcSEcCtD
L-Carnitine—Rash—Doxorubicin—thyroid cancer	0.000126	0.00122	CcSEcCtD
L-Carnitine—Dermatitis—Doxorubicin—thyroid cancer	0.000126	0.00122	CcSEcCtD
L-Carnitine—Headache—Doxorubicin—thyroid cancer	0.000125	0.00121	CcSEcCtD
L-Carnitine—CROT—Metabolism—PPARG—thyroid cancer	0.000125	0.00129	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	0.000121	0.00125	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism—TPR—thyroid cancer	0.000119	0.00124	CbGpPWpGaD
L-Carnitine—Nausea—Doxorubicin—thyroid cancer	0.000118	0.00115	CcSEcCtD
L-Carnitine—CPT1A—Metabolism—PRKAR1A—thyroid cancer	0.000117	0.00122	CbGpPWpGaD
L-Carnitine—SLC22A8—Transmembrane transport of small molecules—CP—thyroid cancer	0.000117	0.00121	CbGpPWpGaD
L-Carnitine—SLC22A8—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000117	0.00121	CbGpPWpGaD
L-Carnitine—SLC22A8—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000115	0.00119	CbGpPWpGaD
L-Carnitine—CPT1A—Circadian rythm related genes—TP53—thyroid cancer	0.000114	0.00119	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—MINPP1—thyroid cancer	0.000112	0.00116	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism—RXRA—thyroid cancer	0.000108	0.00112	CbGpPWpGaD
L-Carnitine—SLC22A4—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000108	0.00112	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.000106	0.0011	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism—PPARG—thyroid cancer	0.000106	0.0011	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism—PPARG—thyroid cancer	0.000106	0.0011	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	0.000105	0.00109	CbGpPWpGaD
L-Carnitine—CROT—Metabolism—PTGS2—thyroid cancer	9.8e-05	0.00102	CbGpPWpGaD
L-Carnitine—SLC22A5—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	9.67e-05	0.001	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—NDUFA13—thyroid cancer	9.54e-05	0.000989	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—CHST14—thyroid cancer	8.97e-05	0.00093	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism—SLC5A5—thyroid cancer	8.92e-05	0.000925	CbGpPWpGaD
L-Carnitine—SLCO1B1—Transmembrane transport of small molecules—TPR—thyroid cancer	8.87e-05	0.000919	CbGpPWpGaD
L-Carnitine—SLCO1B1—Transmembrane transport of small molecules—CP—thyroid cancer	8.87e-05	0.000919	CbGpPWpGaD
L-Carnitine—SLC22A8—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	8.74e-05	0.000906	CbGpPWpGaD
L-Carnitine—SLCO1B1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	8.73e-05	0.000904	CbGpPWpGaD
L-Carnitine—CROT—Metabolism—PTEN—thyroid cancer	8.55e-05	0.000886	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	8.36e-05	0.000866	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism—PTGS2—thyroid cancer	8.33e-05	0.000864	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism—PTGS2—thyroid cancer	8.33e-05	0.000864	CbGpPWpGaD
L-Carnitine—SLC22A5—Transmembrane transport of small molecules—RXRA—thyroid cancer	8.12e-05	0.000842	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—TPR—thyroid cancer	7.89e-05	0.000818	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—PRKAR1A—thyroid cancer	7.77e-05	0.000805	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism—RXRA—thyroid cancer	7.49e-05	0.000777	CbGpPWpGaD
L-Carnitine—SLC22A8—Transmembrane transport of small molecules—RXRA—thyroid cancer	7.35e-05	0.000761	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	7.29e-05	0.000756	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism—PTEN—thyroid cancer	7.27e-05	0.000753	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism—PTEN—thyroid cancer	7.27e-05	0.000753	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—HPGD—thyroid cancer	7.23e-05	0.00075	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism—PPARG—thyroid cancer	6.83e-05	0.000708	CbGpPWpGaD
L-Carnitine—SLCO1B1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	6.64e-05	0.000688	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—SLC5A5—thyroid cancer	5.91e-05	0.000612	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	5.87e-05	0.000608	CbGpPWpGaD
L-Carnitine—SLCO1B1—Transmembrane transport of small molecules—RXRA—thyroid cancer	5.58e-05	0.000578	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism—PTGS2—thyroid cancer	5.37e-05	0.000557	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—RXRA—thyroid cancer	4.96e-05	0.000515	CbGpPWpGaD
L-Carnitine—CROT—Metabolism—AKT1—thyroid cancer	4.93e-05	0.000511	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism—PPARG—thyroid cancer	4.73e-05	0.00049	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism—PTEN—thyroid cancer	4.68e-05	0.000485	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism—AKT1—thyroid cancer	4.19e-05	0.000434	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism—AKT1—thyroid cancer	4.19e-05	0.000434	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—TPR—thyroid cancer	4.15e-05	0.000431	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—PRKAR1A—thyroid cancer	4.09e-05	0.000424	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism—PTGS2—thyroid cancer	3.72e-05	0.000386	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	3.7e-05	0.000384	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism—PTEN—thyroid cancer	3.25e-05	0.000336	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—PPARG—thyroid cancer	3.13e-05	0.000325	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—SLC5A5—thyroid cancer	3.11e-05	0.000322	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.91e-05	0.000302	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism—AKT1—thyroid cancer	2.7e-05	0.00028	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—RXRA—thyroid cancer	2.61e-05	0.000271	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.54e-05	0.000263	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—PTGS2—thyroid cancer	2.47e-05	0.000256	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—PTEN—thyroid cancer	2.15e-05	0.000223	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism—AKT1—thyroid cancer	1.87e-05	0.000194	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—PPARG—thyroid cancer	1.65e-05	0.000171	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—PTGS2—thyroid cancer	1.3e-05	0.000135	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—AKT1—thyroid cancer	1.24e-05	0.000128	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—PTEN—thyroid cancer	1.13e-05	0.000117	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—AKT1—thyroid cancer	6.52e-06	6.76e-05	CbGpPWpGaD
